Results 11 to 20 of about 24,654 (177)

BCR/ABL positive thrombocythemia: a diagnostic dilemma

open access: yesThe Egyptian Journal of Internal Medicine, 2017
Both chronic myeloid leukemia and essential thrombocythemia are part of the spectrum of myeloproliferative neoplasm. Therefore, considerable overlap may occur in the clinical manifestations, and hematological and molecular findings in some patients.
Lubna Zafar   +3 more
doaj   +2 more sources

Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias [PDF]

open access: yesAdvances in Hematology, 2015
BCR-ABL-mediated leukemias, either Chronic Myeloid Leukemia (CML) or Philadelphia positive Acute Lymphoblastic Leukemia (ALL), are the paradigm of targeted molecular therapy of cancer due to the impressive clinical responses obtained with BCR-ABL ...
Alessandro Morotti   +6 more
doaj   +4 more sources

Aleukemic bcr-abl positive granulocytic sarcoma [PDF]

open access: yesLeukemia Research, 2009
Granulocytic sarcoma (GS) can occur de novo or in association with intramedullary myeloid disorders. With the advent of sophisticated molecular detection techniques to detect diagnostic genes such as bcr-abl, PML-RARA and CBFB/MYH11 in bone marrow or peripheral blood, many cases of the so called 'primary' GS are questionable.
Kuan, Jew-Win   +3 more
openaire   +3 more sources

Retraction Note: Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin. [PDF]

open access: yesLeukemia, 2020
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Wu LX   +6 more
europepmc   +4 more sources

Stat5 is indispensable for the maintenance of bcr/abl‐positive leukaemia [PDF]

open access: yesEMBO Molecular Medicine, 2010
Tumourigenesis caused by the Bcr/Abl oncoprotein is a multi-step process proceeding from initial to tumour-maintaining events and finally results in a complex tumour-supporting network. A key to successful cancer therapy is the identification of critical functional nodes in an oncogenic network required for disease maintenance.
Hoelbl A   +14 more
openaire   +2 more sources

Grb10 is involved in BCR-ABL-positive leukemia in mice [PDF]

open access: yesLeukemia, 2014
The SH2-containing adaptor protein Grb10 was first identified in a yeast screen as a new binding partner for BCR-ABL and associates with BCR-ABL in a tyrosine-dependent manner. However, its function in BCR-ABL-mediated leukemogenesis in vivo is still unknown.
Illert, Anna Lena   +6 more
openaire   +3 more sources

Imatinib restores expression of CD62L in BCR-ABL-positive cells [PDF]

open access: yesJournal of Leukocyte Biology, 2003
Abstract Chronic myelogenous leukemia (CML) is characterized by aberrant trafficking of malignant hematopoietic progenitor cells in the peripheral blood. Expression of the cell adhesion molecule CD62L was reported to be significantly lower in CML patients than in normal controls. We studied whether the transcription of CD62L in CML cells
S, Fruehauf   +7 more
openaire   +2 more sources

Acute lymphoblastic leukemia with e1A3 BCR-ABL fusion protein: report of 2 cases and literature review

open access: yesDi-san junyi daxue xuebao, 2021
Objective To investigate the laboratory and clinical characteristics of acute lymphoblastic leukemia (ALL) with e1a3 BCR-ABL fusion protein. Methods The clinical data, and results of bone marrow cytology, flow cytometry, karyotyping, fluorescence in situ
CHEN Siyu   +6 more
doaj   +1 more source

Regulation of hTERT by BCR-ABL at multiple levels in K562 cells

open access: yesBMC Cancer, 2011
Background The cytogenetic characteristic of Chronic Myeloid Leukemia (CML) is the formation of the Philadelphia chromosome gene product, BCR-ABL. Given that BCR-ABL is the specific target of Gleevec in CML treatment, we investigated the regulation of ...
Chai Juin Hsien   +5 more
doaj   +1 more source

Expression of CD66c and CD25 in acute lymphoblastic leukemia as a predictor of the presence of BCR/ABL rearrangement

open access: yesHematology/Oncology and Stem Cell Therapy, 2008
BACKGROUND: Expression of myeloid or T cell lymphoid in precursor B cell acute lymphoblastic leukemia (pre- B cell ALL), which is referred to as aberrant expression, is quite a common phenomenon. cD66c is a myeloid marker which has aberrant expression in
Tarek M. Owaidah   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy